Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 160
- Registration Number
- NCT03069131
- Locations
- 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷CHU de Reims, Reims, France
🇫🇷CHU Amiens, Amiens, France
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02991612
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 308
- Registration Number
- NCT02964195
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Metabolic Consequences of Gastrointestinal Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2019-04-02
- Target Recruit Count
- 81
- Registration Number
- NCT02836353
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Jason Stubbs, MD
- Registration Number
- NCT02738905
- Locations
- 🇺🇸
Westwood Dialysis Center, Westwood, Kansas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02651740
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
GutHeart: Targeting Gut Microbiota to Treat Heart Failure
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02637167
- Locations
- 🇳🇴
Oslo University Hospital - Rikshospitalet, Oslo, Norway
Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
- Conditions
- Interventions
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 24
- Registration Number
- NCT02620007
- Locations
- 🇫🇷
Kremlin-Bicetre hospital, Le Kremlin-Bicêtre, France
🇫🇷Gastroenterology department, Le Kremlin Bicetre, France
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 60
- Registration Number
- NCT02508623
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padua, Italy
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 739
- Registration Number
- NCT02498418
- Locations
- 🇺🇸
Site 1, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.